Combination of TACE and DynaCT-Guided MWA for Liver Tumors ≤5 cm
Overview
This study evaluates the safety and effectiveness of combining transcatheter arterial chemoembolization (TACE) with DynaCT-guided microwave ablation (MWA) for treating liver tumors ≤5 cm in high-risk locations. Results indicate a high objective response rate and favorable survival outcomes, suggesting this combination therapy is a promising option for patients with unresectable liver cancer.
Background
Liver cancer is a significant global health concern, with hepatocellular carcinoma (HCC) being the most prevalent type. Many patients are not candidates for surgical resection due to underlying health conditions or tumor locations. Combining TACE with local ablation therapies like MWA may enhance treatment efficacy, particularly in high-risk areas where traditional methods face limitations.
Data Highlights
Outcome
Value
Mean Overall Survival (OS)
41.0 months (95% CI: 39.6–42.5)
Mean Progression-Free Survival (PFS)
31.2 months (95% CI: 30.7–31.7)
Objective Response Rate (ORR)
96.4%
Disease Control Rate (DCR)
98.2%
Cumulative Survival Rates at 36 months
74.5%
Key Findings
Combination treatment of TACE and MWA was successfully performed on all participants.
Adverse events were primarily classified as grade 1 or 2, indicating mild complications.
The mean OS for patients was 41.0 months, with a mean PFS of 31.2 months.
The ORR one month post-treatment was 96.4%, and the DCR was 98.2%.
Cumulative survival rates at 6, 12, 24, and 36 months were 98.1%, 94.5%, 85.4%, and 74.5%, respectively.
Clinical Implications
The findings support the use of TACE combined with DynaCT-guided MWA as a viable treatment strategy for patients with liver tumors in high-risk locations. Clinicians should consider this approach for patients who are not suitable for surgical resection, as it demonstrates high efficacy and manageable safety profiles.
Conclusion
The combination of TACE and DynaCT-guided MWA presents a safe and effective treatment option for liver tumors ≤5 cm in high-risk locations, potentially improving patient outcomes in this challenging clinical scenario.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
